Back to top
more

ANI Pharmaceuticals, Inc. (ANIP)

(Delayed Data from NSDQ)

$73.96 USD

73.96
202,813

+1.46 (2.01%)

Updated Jun 18, 2019 03:58 PM ET

Add to portfolio

4-Sell       4  

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1
2
3
4
5
S&P
Strong Buy
Buy
Hold
Sell
Strong Sell
500
24.91%
17.98%
9.64%
5.22%
2.12%
10.58%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

B Value | A Growth | B Momentum | A VGM

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

View All Zacks #1 Ranked Stocks

Trades from $1

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Zacks News

Zacks Equity Research

What Makes ANI (ANIP) a New Buy Stock

ANI (ANIP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

ANIP

Zacks Equity Research

ANI Pharmaceuticals (ANIP) Dips More Than Broader Markets: What You Should Know

ANI Pharmaceuticals (ANIP) closed at $70.24 in the latest trading session, marking a -1.04% move from the prior day.

ANIP

Zacks Equity Research

The Zacks Analyst Blog Highlights: Bed Bath & Beyond, ANI, DXP, Foot Locker and ACI

The Zacks Analyst Blog Highlights: Bed Bath & Beyond, ANI, DXP, Foot Locker and ACI

ACIW DXPE ANIP FL BBBY

Zacks Equity Research

What's in Store for ANI Pharmaceuticals (ANIP) Q1 Earnings?

ANI Pharmaceuticals (ANIP) will provide updates on product launches, when it releases first-quarter 2019 results.

GSK NVO ANIP GILD

Tirthankar Chakraborty

American Economy Hits the Gas: 5 Top Gainers

The U.S. economy grew 3.2% in the first quarter of 2019, primarily on two typically volatile components - inventories and trade.

ACIW DXPE ANIP FL BBBY

Zacks Equity Research

Medicines Company (MDCO) Q1 Loss Narrows, Inclisiran in Focus

The Medicines Company (MDCO) suffers narrower-than-expected loss in Q1. The company progresses well with its sole pipeline candidate, inclisiran.

ALNY CLSN ANIP MDCO

Zacks Equity Research

ANI Pharmaceuticals (ANIP) Dips More Than Broader Markets: What You Should Know

ANI Pharmaceuticals (ANIP) closed at $69.66 in the latest trading session, marking a -0.49% move from the prior day.

ANIP

Zacks Equity Research

Alexion (ALXN) Q1 Earnings Beat Estimates, Guidance Raised

Alexion (ALXN) beats earnings and sales estimates in the first quarter of 2019 and raises guidance for the year.

ANIP ALXN CLSN RCUS

Zacks Equity Research

Zacks.com featured expert Kevin Matras highlights: Advanced Emissions Solutions, Verint Systems, Great Lakes Dredge & Dock, ANI Pharmaceuticals and ACI Worldwide

Zacks.com featured expert Kevin Matras highlights: Advanced Emissions Solutions, Verint Systems, Great Lakes Dredge & Dock, ANI Pharmaceuticals and ACI Worldwide

GLDD VRNT ACIW ANIP ADES

Nalak Das

5 Stocks With Recent Price Strength to Enhance Your Returns

Investors target stocks that have been on a bullish run lately. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.

GLDD VRNT ACIW ANIP ADES

Zacks Equity Research

ANI Pharmaceuticals (ANIP) Stock Sinks As Market Gains: What You Should Know

In the latest trading session, ANI Pharmaceuticals (ANIP) closed at $68.88, marking a -0.17% move from the previous day.

ANIP

Zacks Equity Research

Ultragenyx's (RARE) UX007 Gets Fast Track Status by FDA

Ultragenyx???s (RARE) UX007 receives Fast Track designation and Rare Pediatric Disease designation by the FDA for the treatment of long-chain fatty acid oxidation disorders.

BAYRY RARE ANIP CLSN

Zacks Equity Research

QIAGEN Drives Molecular Diagnostics Suite With New Test Kit

QIAGEN (QGEN) introduces the FDA approved companion diagnostic test to help in guiding therapy in any cancer identification.

ADXS QGEN ANIP XRAY

Zacks Equity Research

Has ANI Pharmaceuticals (ANIP) Outpaced Other Medical Stocks This Year?

Is (ANIP) Outperforming Other Medical Stocks This Year?

ANIP

Zacks Equity Research

3 Reasons Why Growth Investors Shouldn't Overlook ANI (ANIP)

ANI (ANIP) could produce exceptional returns because of its solid growth attributes.

ANIP

Zacks Equity Research

ANI Pharmaceuticals (ANIP) Outpaces Stock Market Gains: What You Should Know

In the latest trading session, ANI Pharmaceuticals (ANIP) closed at $69.44, marking a +1.71% move from the previous day.

ANIP

Moumita Chattopadhyay

5 Stocks With Increasing Cash Flows to Scoop Up Big Gains

Cash gives a company vitality and strength. It holds the key to its existence, development and success, and can indeed be referred to as its lifeblood.

FBP WD KMDA ANIP BBSI

Zacks Equity Research

Zacks.com featured expert Kevin Matras highlights: Herc, ANI Pharmaceuticals, Kamada, SP Plus and SkyWest

Zacks.com featured expert Kevin Matras highlights: Herc, ANI Pharmaceuticals, Kamada, SP Plus and SkyWest

SKYW HRI KMDA ANIP SP

Zacks Equity Research

BioDelivery (BDSI) Buys US Rights to Pain Drug for $30M

BioDelivery Sciences (BDSI) announces acquisition of U.S. commercial rights to pain drug, Symproic, from Japanese company, Shinogi.

ANIP BDSI KMDA TEVA

Zacks Equity Research

Tap These 6 Stocks That Flaunt Sizeable Net Profit Margin

Here are six stocks with spectacular net profit margins that investors can bank on for stellar returns.

SKYW HRI SNX KMDA ANIP SP

Zacks Equity Research

PhaseBio Stock Up on Breakthrough Therapy Status for PB2452

FDA grants PhaseBio's (PHAS) lead pipeline candidate, PB2452, Breakthrough Therapy status for treating bleeding risk associated with, AstraZeneca's antiplatelet drug Brilinta.

AZN ANIP KMDA PHAS

Zacks Equity Research

Coherus (CHRS) Catches Eye: Stock Jumps 6.9%

Coherus (CHRS) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

CHRS ANIP

Zacks Equity Research

Seattle Genetics (SGEN) Surges: Stock Moves 7.6% Higher

Seattle Genetics (SGEN) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

ANIP SGEN

Zacks Equity Research

ANI Pharmaceuticals (ANIP) Stock Sinks As Market Gains: What You Should Know

In the latest trading session, ANI Pharmaceuticals (ANIP) closed at $70.39, marking a -0.13% move from the previous day.

ANIP

Zacks Equity Research

Palatin Technologies (PTN) in Focus: Stock Moves 5.7% Higher

Palatin Technologies (PTN) shares rose nearly 6% in the last trading session, amid huge volumes.

ANIP PTN